WEBULL
WebtradeDownload

uniQure (QURE) Could Be 36% Undervalued Following Its AMT 130 FDA Filing

Simply Wall St · 1d ago

Regulatory catalyst for uniQure

uniQure (QURE) has moved into a new phase with its Biologics License Application to the U.S. FDA and a parallel UK filing for AMT-130, an investigational Huntington’s disease gene therapy.

Recent trading has been choppy for uniQure, with the share price down 7% over the past week and 4% over the past month. However, a 66% 90 day share price return and a 1 year total shareholder return of 154% signal momentum that has been building around the stock as AMT-130 advances through the regulatory process.

Scan other potential Huntington’s and rare-disease beneficiaries by reviewing the hand-picked 37 healthcare AI stocks, which could also see attention as gene therapies like uniQure’s move through regulators.

After a 154% 1 year total return and a 90 day move of 66%, uniQure now raises a tougher question for new capital: do you step in after this run, or wait and let valuation dictate the next move?

Most Popular Narrative: 36% Undervalued

Against a last close of $44.50, the most followed valuation narrative for uniQure pins fair value nearer $69, which sets up a wide gap investors are trying to explain.

The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.

Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that gap between price and fair value for uniQure? The story leans heavily on rapid top line expansion and a sharp swing into profitability. It also assumes a rich future earnings multiple that many investors normally associate with high growth franchises. Curious which specific revenue path and margin profile have to line up to make those numbers work.

Result: Fair Value of $69.38 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the uniQure story leans heavily on AMT-130 clearing regulators on the expected timetable and on outsourced manufacturing running smoothly without costly supply disruptions.

Find out about the key risks to this uniQure narrative.

Another View on uniQure’s valuation

The story so far leans heavily on future earnings and cash flows. Our DCF model presents an even more stretched picture, with uniQure trading around $44.50 against an estimated future cash flow value of $387.38, which also points to undervaluation. Is that a margin of safety, or a sign expectations are running too hot?

Look into how the SWS DCF model arrives at its fair value.

QURE Discounted Cash Flow as at Sep 2026
QURE Discounted Cash Flow as at Sep 2026

Next Steps

Big moves in uniQure can make the story feel either exciting or fragile. Consider acting promptly and weighing both sides of the debate by checking the 2 key rewards and 3 important warning signs.

Looking for more uniQure-sized ideas?

Do not stop with uniQure. Use the Simply Wall Street Screener to uncover other opportunities that fit your approach before the crowd catches up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.